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To the Editor: 
Dr Dabelea and colleagues1 provided much needed data on the natural history of complications 
in adolescents and young adults with diabetes. We agree that the increasing number of children 
and adolescents living with diabetes calls for strategies to reduce the development of diabetic 
complications in early adulthood.  With regards to diabetic eye disease, such strategies require a 
deeper understanding than currently available of the natural history of diabetic retinopathy. 
Specifically, analyses of the prevalence of and progression to retinopathy requiring treatment are 
needed. 
The taxonomy used by Dabelea and colleagues combined all grades of diabetic retinopathy into 
one category, ie, they considered early mild non-proliferative and blinding proliferative 
retinopathy together. This is uninformative and potentially misleading.  
Since management of diabetic retinopathy varies by severity, ranging from continuation of 
routine screening to ophthalmic interventions such as laser therapy,2 reporting that the overall 
prevalence of diabetic retinopathy in adolescents and young adults living with type 1 and type 2 
diabetes as 5.6% and 9.1%, respectively, does not serve to inform pediatric diabetic retinopathy 
care pathways. Screening programs for diabetic retinopathy aim primarily to prevent visual loss 
by early identification and opportune treatment of sight-threatening retinopathy, ie, severe non-
proliferative or more advanced stages that might benefit from treatment with laser therapy or 
intravitreal anti-vascular endothelial growth factor therapy.2 Knowledge of the prevalence and 
risk factors for each of these stages is necessary to the debate on whether screening 
recommendations for diabetic retinopathy in children and adolescents should be modified.3 The 
Diabetic Eye Disease in Childhood Study (DECS), currently underway in the United Kingdom, 
aims to fill some of these gaps in the evidence base.4  
Evidence has emerged in adult populations of the clinical utility of the identification of early 
diabetic complications as a driver of improvements in glycemic control.5 However, it is unclear 
whether the same holds true for children and adolescents with early stages of diabetic 
retinopathy.  We disagree with Dabelea and colleagues that “mild non-proliferative diabetic 
retinopathy or more severe stages” is the relevant endpoint for planning monitoring or 
investigating the epidemiology of retinopathy in children and adolescents living with diabetes. 
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